A citation-based method for searching scientific literature

Adie Viljoen, Christina S Hoxer, Pierre Johansen, Samuel Malkin, Barnaby Hunt, Stephen C Bain. Diabetes Obes Metab 2019
Times Cited: 20







List of co-cited articles
110 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
225
65

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
65

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Andrew J Palmer, Stéphane Roze, William J Valentine, Michael E Minshall, Volker Foos, Francesco M Lurati, Morten Lammert, Giatgen A Spinas. Curr Med Res Opin 2004
350
60

Validation of the IMS CORE Diabetes Model.
Phil McEwan, Volker Foos, James L Palmer, Mark Lamotte, Adam Lloyd, David Grant. Value Health 2014
116
55

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Andrew J Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G Holst, Miriam P Annett, Vanita R Aroda. Diabetes Care 2018
178
55


Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries.
Marc Evans, Kamlesh Khunti, Muhammad Mamdani, Claus B Galbo-Jørgensen, Jens Gundgaard, Mette Bøgelund, Stewart Harris. Health Qual Life Outcomes 2013
109
50

Validation of the CORE Diabetes Model against epidemiological and clinical studies.
Andrew J Palmer, Stéphane Roze, William J Valentine, Michael E Minshall, Volker Foos, Francesco M Lurati, Morten Lammert, Giatgen A Spinas. Curr Med Res Opin 2004
210
45

Review of utility values for economic modeling in type 2 diabetes.
Amélie Beaudet, John Clegg, Per-Olof Thuresson, Adam Lloyd, Phil McEwan. Value Health 2014
96
45



10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
45

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
45

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
40

Effect of a multifactorial intervention on mortality in type 2 diabetes.
Peter Gaede, Henrik Lund-Andersen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2008
40

Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.
Craig J Currie, Christopher Ll Morgan, Chris D Poole, Peter Sharplin, Morten Lammert, Phil McEwan. Curr Med Res Opin 2006
188
40


Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.
Simon J Griffin, Knut Borch-Johnsen, Melanie J Davies, Kamlesh Khunti, Guy E H M Rutten, Annelli Sandbæk, Stephen J Sharp, Rebecca K Simmons, Maureen van den Donk, Nicholas J Wareham,[...]. Lancet 2011
303
35

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
Faramarz Ismail-Beigi, Timothy Craven, Mary Ann Banerji, Jan Basile, Jorge Calles, Robert M Cohen, Robert Cuddihy, William C Cushman, Saul Genuth, Richard H Grimm,[...]. Lancet 2010
818
35


Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
35

Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.
Pedro Mezquita-Raya, Antonio Ramírez de Arellano, Nana Kragh, Gabriela Vega-Hernandez, Johannes Pöhlmann, William J Valentine, Barnaby Hunt. Diabetes Ther 2017
12
50



Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.
Pierre Johansen, Jonas Håkan-Bloch, Aiden R Liu, Peter G Bech, Sofie Persson, Lawrence A Leiter. Pharmacoecon Open 2019
8
75

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
Samuel J P Malkin, Monika Russel-Szymczyk, Girtel Liidemann, Vallo Volke, Barnaby Hunt. Diabetes Ther 2019
7
85

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Peter Gæde, Pierre Johansen, Christian Klyver Tikkanen, Richard Fulton Pollock, Barnaby Hunt, Samuel Joseph Paul Malkin. Diabetes Ther 2019
10
60


A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).
P M Clarke, A M Gray, A Briggs, A J Farmer, P Fenn, R J Stevens, D R Matthews, I M Stratton, R R Holman. Diabetologia 2004
383
25

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
P M Kearney, L Blackwell, R Collins, A Keech, J Simes, R Peto, J Armitage, C Baigent. Lancet 2008
25

Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
Barnaby Hunt, Gabriela Vega-Hernandez, William J Valentine, Nana Kragh. Diabetes Obes Metab 2017
14
35

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.
Christoph Stettler, Sabin Allemann, Peter Jüni, Carole A Cull, Rury R Holman, Matthias Egger, Stephan Krähenbühl, Peter Diem. Am Heart J 2006
302
25

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Helena W Rodbard, Ildiko Lingvay, John Reed, Raymond de la Rosa, Ludger Rose, Danny Sugimoto, Eiichi Araki, Pei-Ling Chu, Nelun Wijayasinghe, Paul Norwood. J Clin Endocrinol Metab 2018
97
25

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Christopher Sorli, Shin-Ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen, Stephen C Bain. Lancet Diabetes Endocrinol 2017
177
25

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
25

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetologia 2018
541
25

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
829
25

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
700
25


Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Barnaby Hunt, Nana Kragh, Ceilidh C McConnachie, William J Valentine, Maria C Rossi, Roberta Montagnoli. Clin Ther 2017
13
30

The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes.
Eva K Fenwick, Jing Xie, Julie Ratcliffe, Konrad Pesudovs, Robert P Finger, Tien Y Wong, Ecosse L Lamoureux. Invest Ophthalmol Vis Sci 2012
52
20

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
20

Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries.
Jørgen T Lauridsen, Jonas Lønborg, Jens Gundgaard, Henrik Holm Jensen. Qual Life Res 2014
28
20

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
634
20

The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Samuel J P Malkin, Monika Russel-Szymczyk, Marek Psota, Lucia Hlavinkova, Barnaby Hunt. Adv Ther 2019
4
100

What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
Seamus Kent, Iryna Schlackow, Jingky Lozano-Kühne, Christina Reith, Jonathan Emberson, Richard Haynes, Alastair Gray, Alan Cass, Colin Baigent, Martin J Landray,[...]. BMC Nephrol 2015
49
15




Costs of managing severe hypoglycaemia in three European countries.
Mette Hammer, Morten Lammert, Susana Monereo Mejías, Werner Kern, Brian M Frier. J Med Econ 2009
99
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.